Gilead Sciences (GILD) Deferred Taxes (2009 - 2026)
Gilead Sciences' (GILD) quarterly Deferred Taxes came in at $179.0 million in Q1 2026, up 189.95% YoY from $61.7 million in Q1 2025, and up 246.72% on a QoQ basis from -$122.0 million in Q4 2025.
Gilead Sciences (GILD) Deferred Taxes (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Deferred Taxes data on file, last reported at $179.0 million in Q1 2026.
- Quarterly Deferred Taxes rose 189.95% year-over-year to $179.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $538.0 million (up 140.76% YoY) and the FY2025 annual result came in at $160.0 million, up 108.68% from the prior year.
- Deferred Taxes rose to $179.0 million in Q1 2026, from -$122.0 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $659.0 million in Q3 2025 to a low of -$723.0 million in Q1 2024.
- A 5-year average of -$236.4 million and a median of -$270.0 million in 2022 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2022 — Deferred Taxes tumbled 1016.9% — and 2025, when it surged 214.41%.
- Tracing GILD's Deferred Taxes over 5 years: stood at -$338.0 million in 2022, then slipped by 9.47% to -$370.0 million in 2023, then retreated by 2.43% to -$379.0 million in 2024, then soared by 67.81% to -$122.0 million in 2025, then surged by 246.72% to $179.0 million in 2026.
- The last three Deferred Taxes figures came in at $179.0 million (Q1 2026), -$122.0 million (Q4 2025), and $659.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.90 Bn | 633.14 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 470.19 Bn | 463.62 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 377.19 Bn | 370.05 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.67 Bn | 252.77 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.95 Bn | 222.96 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -587.00 Mn |
| Mar 31, 2026 | 179.00 Mn |
| Dec 31, 2025 | -122.00 Mn |
| Sep 30, 2025 | 659.00 Mn |
| Jun 30, 2025 | -178.00 Mn |
| Mar 31, 2025 | -199.00 Mn |
| Dec 31, 2024 | -379.00 Mn |
| Sep 30, 2024 | -576.00 Mn |
| Jun 30, 2024 | -166.00 Mn |
| Mar 31, 2024 | -723.00 Mn |
| Dec 31, 2023 | -370.00 Mn |
| Sep 30, 2023 | -68.00 Mn |
| Jun 30, 2023 | -221.00 Mn |
| Mar 31, 2023 | -303.00 Mn |
| Dec 31, 2022 | -338.00 Mn |
| Sep 30, 2022 | -270.00 Mn |
| Jun 30, 2022 | -293.00 Mn |
| Mar 31, 2022 | -651.00 Mn |
| Dec 31, 2021 | -359.00 Mn |
| Sep 30, 2021 | 240.00 Mn |